Oral Antiviral Therapeutics to Combat COVID-19 More Available in Tennessee


The two oral antiviral therapeutics developed by pharmaceutical companies Merck and Pfizer to treat mild to moderate cases of COVID-19 are readily available to patients in Tennessee as a part of an increased bi-weekly allocation program.

“This increase in allocations is something we have been anticipating for weeks,” Tennessee Department of Health Commissioner Dr. Lisa Piercey, MD, MBA, FAAP said in a statement. “Our goal has always been to increase access to these treatments by onboarding more pharmacies to maximize access to patients. We have seen a steady increase in allocations to the state and know many pharmacies and providers are eager to offer this treatment to help mitigate COVID-19 disease progression for those at risk of a severe outcome.”

Read More

Merck Says Its COVID-19 Pill Is Less Effective than Initially Reported

Merck announced Friday that updated data on its experimental COVID-19 pill show the drug is less effective than previously reported, and will now move to test treatment for safety.

Merck said the pill, Molnupiravir, showed a 30% reduction in hospitalization and deaths based on data from roughly 1,400 patients. Figures from an interim study released Oct. 1 showed an approximately 50% efficacy based on data from over 1,400 patients.

Read More